6-(imidazo[1,2-a]pyridin-6-yl)-8-(4-methoxyphenyl)-2-((2,2,2-trifluoroethyl)amino)pyrido[4,3-d]pyrimidin-7(6H)-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-(imidazo[1,2-a]pyridin-6-yl)-8-(4-methoxyphenyl)-2-((2,2,2-trifluoroethyl)amino)pyrido[4,3-d]pyrimidin-7(6H)-one
• 英文别名: 6-Imidazo[1,2-a]pyridin-6-yl-8-(4-methoxyphenyl)-2-(2,2,2-trifluoroethylamino)pyrido[4,3-d]pyrimidin-7-one；6-imidazo[1,2-a]pyridin-6-yl-8-(4-methoxyphenyl)-2-(2,2,2-trifluoroethylamino)pyrido[4,3-d]pyrimidin-7-one
• 化学式: C₂₃H₁₇F₃N₆O₂
• 分子量: 466.422
• InChiKey: RTDHKMLBCWYKIG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  83.6
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  8-(4-methoxyphenyl)-2-((2,2,2-trifluoroethyl)amino)pyrido[4,3-d]pyrimidin-7(6H)-one 、 6-溴-咪唑并[1,2-a]吡啶 在 copper(l) iodide 、 cesium fluoride 、 N,N'-二甲基-1,2-环己二胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 16.0h， 生成 6-(imidazo[1,2-a]pyridin-6-yl)-8-(4-methoxyphenyl)-2-((2,2,2-trifluoroethyl)amino)pyrido[4,3-d]pyrimidin-7(6H)-one
  参考文献：
  名称：

  WO2019191470A5

  摘要：

  公开号：

  WO2019191470A5

文献信息

• Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
  申请人：AGIOS PHARMACEUTICALS, INC.

  公开号：US11524960B2

  公开（公告）日：2022-12-13

  The present disclosure provides for compounds according to Formula I or Formula II and their pharmaceutically acceptable salts, stereoisomers, and/or tautomers thereof. Also provided are pharmaceutical compositions and the compounds of formulae I and II for use in methods of treating cancers, via inhibition of MAT2A, including some cancers in which the gene encoding methylthioadenosine phosphorylase (MTAP) is deleted and/or not fully functioning.

  本公开提供了根据式 I 或式 II 的化合物及其药学上可接受的盐、立体异构体和/或同系物。还提供了药物组合物和式 I 和 II 的化合物，用于通过抑制 MAT2A 治疗癌症的方法，包括一些编码甲硫腺苷磷酸化酶（MTAP）的基因被删除和/或不能完全发挥作用的癌症。
• HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER
  申请人：AGIOS PHARMACEUTICALS, INC.

  公开号：US20210115045A1

  公开（公告）日：2021-04-22

  The present disclosure provides for compounds according to Formula I or Formula II and their pharmaceutically acceptable salts, stereoisomers, and/or tautomers thereof. Also provided are pharmaceutical compositions and the compounds of formulae I and II for use in methods of treating cancers, via inhibition of MAT2A, including some cancers in which the gene encoding methylthioadenosine phosphorylase (MTAP) is deleted and/or not fully functioning.
• [EN] HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER<br/>[FR] INHIBITEURS HÉTÉROBICYCLIQUES DE MAT2A ET LEURS MÉTHODES D'UTILISATION POUR LE TRAITEMENT DU CANCER
  申请人：AGIOS PHARMACEUTICALS INC

  公开号：WO2019191470A1

  公开（公告）日：2019-10-03

  The present disclosure provides for compounds according to Formula I or Formula II and their pharmaceutically acceptable salts, stereoisomers, and/or tautomers thereof,.Also provided are pharmaceutical compositions and the compounds of formulae I and II for use in methods of treating cancers via inhibition of MAT2B, including some cancers in which the gene encoding methylthioadenosine phosphorylase (MTAP) is deleted.
• WO2019191470A5
  申请人：——

  公开号：WO2019191470A5

  公开（公告）日：2022-04-05